Actinium Pharmaceuticals, Inc. SEC filings ATNM
Actinium Pharmaceuticals, Inc. has 511 filings in SEC EDGAR's recent list, going back to Feb 5, 2007. Its latest annual report, Form ARS, was filed on Oct 15, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 7, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 15, 2026 (officer or director change, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Feb 5, 2024 | — |
| CORRESP | Letter to the SEC | Feb 2, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 17, 2023 | — |
| EFFECT | Filing | Aug 14, 2020 | — |
| CORRESP | Letter to the SEC | Aug 14, 2020 | — |
| UPLOAD | Letter from the SEC | Aug 13, 2020 | — |
| EFFECT | Filing | Oct 12, 2017 | — |
| CORRESP | Letter to the SEC | Oct 10, 2017 | — |
| UPLOAD | Letter from the SEC | Oct 5, 2017 | — |
| CORRESP | Letter to the SEC | Oct 3, 2017 | — |
| CORRESP | Letter to the SEC | Oct 3, 2017 | — |
| UPLOAD | Letter from the SEC | Sep 26, 2017 | — |
| NT 10-Q | Notification of late filing | May 10, 2017 | Mar 31, 2017 |
| UPLOAD | Letter from the SEC | Apr 5, 2017 | — |
| EFFECT | Filing | Apr 17, 2014 | — |
| CORRESP | Letter to the SEC | Apr 16, 2014 | — |
| CORRESP | Letter to the SEC | Apr 10, 2014 | — |
| UPLOAD | Letter from the SEC | Apr 1, 2014 | — |
| CERTNYS | Auto-generated paper document | Mar 25, 2014 | — |
| 8-A12B | Form 8-a | Mar 24, 2014 | — |
| EFFECT | Filing | Feb 13, 2014 | — |
| D/A | Filing | Jan 21, 2014 | — |
| D | Filing | Jan 7, 2014 | — |
| UPLOAD | Letter from the SEC | Nov 25, 2013 | — |
| PRER14A | Preliminary proxy statement amendment | Nov 22, 2013 | — |
| CORRESP | Letter to the SEC | Nov 21, 2013 | — |
| UPLOAD | Letter from the SEC | Nov 21, 2013 | — |
| EFFECT | Filing | Nov 8, 2013 | — |
| CORRESP | Letter to the SEC | Nov 6, 2013 | — |
| CORRESP | Letter to the SEC | Oct 28, 2013 | — |
| UPLOAD | Letter from the SEC | Oct 24, 2013 | — |
| D | Filing | Oct 8, 2013 | — |
| CORRESP | Letter to the SEC | Sep 30, 2013 | — |
| RW | Withdawal request | Sep 30, 2013 | — |
| UPLOAD | Letter from the SEC | Sep 19, 2013 | — |
| D | Filing | Sep 4, 2013 | — |
| CORRESP | Letter to the SEC | Aug 22, 2013 | — |
| UPLOAD | Letter from the SEC | Apr 12, 2013 | — |
| D | Filing | Mar 19, 2013 | — |
| D | Filing | Jan 14, 2013 | — |
| SC 14F1 | Schedule 14f-1 information statement | Jan 3, 2013 | — |
| NT 10-Q | Form 12b-25 | Aug 15, 2012 | Jun 30, 2012 |
| NT 10-K | Form 12b-25 | Mar 30, 2012 | Dec 31, 2011 |
| UPLOAD | Letter from the SEC | Jan 11, 2010 | — |
| CORRESP | Letter to the SEC | Dec 28, 2009 | — |
| CORRESP | Letter to the SEC | Dec 28, 2009 | — |
| UPLOAD | Letter from the SEC | Dec 15, 2009 | — |
| UPLOAD | Letter from the SEC | Nov 13, 2009 | — |
| 10KSB/A | Cactus ventures, inc. 10ksb/a 12.31.07 | Apr 4, 2008 | Dec 31, 2007 |
| 10KSB | Cactus ventures, inc. 10ksb 12.31.2007 | Feb 12, 2008 | Dec 31, 2007 |
| 10QSB | Cactus ventures, inc. 10 qsb 9.30.2007 | Nov 13, 2007 | Sep 30, 2007 |
| 10QSB | Cactus ventures, inc. 10qsb 6.30.07 | Aug 14, 2007 | Jun 30, 2007 |
| 10QSB | Cactus ventures inc 10qsb 3312007 | May 10, 2007 | Mar 31, 2007 |
| 10SB12G | Form 10-sb registration statement | Feb 5, 2007 | — |
Showing 54 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ATNM (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1388320
- Former names
- Cactus Ventures, Inc. (until Mar 29, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.